Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S1W-12788 · Session 1

Whether the recent National Institute of Clinical Excellence ruling on Aricept will mean that Al'heimer's patients across Scotland will hav…

Answered Asked by Mary Scanlon Con Lodged 24 Jan 2001

The question

To ask the Scottish Executive whether the recent National Institute of Clinical Excellence ruling on Aricept will mean that Al'heimer's patients across Scotland will have access to the drug.

The answer

Answered by Susan Deacon on 7 Feb 2001 · 14 days after it was lodged, on time

The Health Technology Board for Scotland is currently working on a process to comment on all Final Appraisals from the National Institute for Clinical Excellence (NICE). The NICE Appraisal on donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl) will be the first to go through this process in the spring.As an interim measure, the Scottish Executive has asked Drugs and Therapeutics Committees to review any advice they may have provided to their clinicians on the use of these treatments in Alzheimer's disease, taking into account the NICE advice.

In the Official Report

No contribution in the Official Report cites S1W-12788 by reference.